198 related articles for article (PubMed ID: 35804176)
21. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
Storgard R; Markova A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
[TBL] [Abstract][Full Text] [Related]
23. Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.
Park BC; Jung S; Chen ST; Dewan AK; Johnson DB
Am J Clin Dermatol; 2022 Sep; 23(5):707-717. PubMed ID: 35708849
[TBL] [Abstract][Full Text] [Related]
24. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond "maculopapular rash".
Allais BS; Fay CJ; Kim DY; Semenov YR; LeBoeuf NR
Immunol Rev; 2023 Sep; 318(1):22-36. PubMed ID: 37583051
[TBL] [Abstract][Full Text] [Related]
26. Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study.
Storm BN; Abedian Kalkhoran H; Wilms EB; Brocken P; Codrington H; Houtsma D; Portielje JEA; de Glas N; van der Ziel D; van den Bos F; Visser LE
J Geriatr Oncol; 2022 Sep; 13(7):997-1002. PubMed ID: 35668012
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
28. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N; Wan G; Ugwu-Dike P; Alexander NA; Raval N; Zhang S; Jairath R; Phillipps J; Leung B; Roster K; Seo J; Lu C; Tang K; Choi MS; DeSimone MS; Theodosakis N; Amadife M; Cox N; Le TK; Liu F; Chen W; Bai X; Boland G; Liu D; Hurlbert MS; LeBoeuf N; Reynolds KL; Yu KH; Tsao H; Asgari M; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1308-1316. PubMed ID: 36828138
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Chen CH; Yu HS; Yu S
Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity. A prospective study of 189 patients treated with checkpoint inhibitors in a Spanish tertiary care hospital.
Juan-Carpena G; Martínez Banaclocha N; Palazón-Cabanes JC; Niveiro-de Jaime M; Betlloch-Mas I; Blanes-Martínez M
Clin Exp Dermatol; 2024 Feb; ():. PubMed ID: 38372424
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.
Tattersall IW; Leventhal JS
Yale J Biol Med; 2020 Mar; 93(1):123-132. PubMed ID: 32226342
[TBL] [Abstract][Full Text] [Related]
32. [Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)].
; ;
Zhonghua Yi Xue Za Zhi; 2024 May; 104(20):1790-1803. PubMed ID: 38782747
[TBL] [Abstract][Full Text] [Related]
33. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
34. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
[TBL] [Abstract][Full Text] [Related]
35. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
36. Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
Hajem S; Ederhy S; Champiat S; Troalen F; Nolin-Lapalme A; Berhoune M; Cauquil C; Martin-Romano P; Baldini C; Laparra A; Vuagnat P; Hollebecque A; Mateus C; Besse B; Naltet C; Robert C; Marabelle A; Massard C; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 157():383-390. PubMed ID: 34571335
[TBL] [Abstract][Full Text] [Related]
37. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
38. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
Keiser MF; Patel AB; Altan M
Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of Skin Cancer Diagnosis by Physician Assistants Compared With Dermatologists in a Large Health Care System.
Anderson AM; Matsumoto M; Saul MI; Secrest AM; Ferris LK
JAMA Dermatol; 2018 May; 154(5):569-573. PubMed ID: 29710082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
